This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

    More

    Page   1/5   
  • Measuring the return from pharmaceutical innovation 2013
    For the last four years Deloitte and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines.
  • Impact of European Austerity on Pharmaceutical policy and pricing
    A UK Deloitte Centre for Health solutions report that looks to understand the current European pharmaceutical market, the mechanisms for reducing pharmaceutical spending, the future of the pharmaceutical landscape, and the actions the pharmaceutical industry needs to take to survive current austerity.
  • Measuring the return from pharmaceutical innovation 2012
    For the last three years, Deloitte LLP and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines.
  • Page   1/5   
Stay connected
Get connected
Share your comments